Annual rank59
Denmark · Healthcare
ALK-Abello
Develops allergy-immunotherapy treatments and management solutions forming the core of its current product portfolio.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Allergy immunotherapy from natural source material to finished medicines
ALK-Abello is a Danish specialist in allergy immunotherapy, medicines made from carefully standardised allergens to change the body's response to a specific trigger over time. Its portfolio includes tablets, injections and drops for respiratory and venom allergies, plus diagnostics, consumer products and emergency adrenaline formats. The group controls an unusual chain from cultivating pollen and other biological materials to clinical development, pharmaceutical production and distribution across 46 markets.
Allergy immunotherapy
The same principle delivered as tablet, injection or drops
ALK uses controlled exposure to a defined allergen to alter the immune response over time. Its formats include clinician-administered injections and sublingual drops or fast-dissolving tablets; marketed tablets cover allergens such as house dust mite, grass, ragweed and Japanese cedar in different countries.
- Allergy-vaccine formats How tablets, injections and drops differ in administration
- How immunotherapy works ALK's scientific explanation of the immune response
- Clinical-trial programme How ALK studies SLIT tablets with hospitals and specialists
- Science and technology Fast-dissolving tablets, biobank data and research partnerships
From farm to pharma
Pollen, mites and venom become standardised medicines
Natural starting materials create a manufacturing challenge: biological variation must not become product variation. ALK grows or collects pollen, mites, venom, food proteins and pet dander, then identifies, extracts, purifies and standardises them before formulation. Its US source-material operation spans farms and facilities in Pennsylvania, California and Washington.
- Production network The farm-to-pharma model and production in Europe and the US
- US source-material farms Cultivation, pollen collection, identity testing and distribution
- ▶ VideoWatch: from farm to pharma ALK's English-subtitled journey from natural material to medicine
- Four production steps Harvesting, extraction, formulation, packaging and distribution
Beyond long-term treatment
Diagnosis, daily management and emergency adrenaline
ALK also makes allergen extracts for diagnostic skin-prick testing and operates in consumer allergy care. For acute anaphylaxis, its portfolio spans an adrenaline auto-injector and the ARS-developed neffy nasal spray in markets where ALK holds commercial rights. Following Health Canada's April 2026 approval, ALK launched neffy 2 mg on 5 August for adults and children weighing at least 30 kg; the 1 mg dose for children weighing 15–30 kg remained under Canadian review.
- Emergency medicine ALK's adrenaline formats and anaphylaxis focus
- neffy launched in Canada The 5 August 2026 launch of the licensed 2 mg nasal spray for patients weighing at least 30 kg
- Allergy diagnostics Allergen extracts used alongside history and skin-prick tests
- Consumer healthcare Everyday products and digital routes into allergy management
Reach and next research questions
A specialist platform expands into food allergy and data science
ALK reports production in Denmark, France, Spain and the US, offices in more than 20 countries and activity in 46 markets. Its Allergy+ strategy extends respiratory tablets towards food allergy, anaphylaxis and adjacent conditions. Research examples include an investigational peanut SLIT tablet, digital discovery tools and work with McMaster University on IgE memory B cells.
- Company and global footprint Production countries, offices, markets and a century of milestones
- Allergy+ strategy Respiratory tablets, food allergy, anaphylaxis and adjacent areas
- Digital innovation Data platforms, target discovery, apps and wearable-device research
- Peanut-tablet programme The phase II outcome and planned late-2026 phase III start
- The cell that remembers allergy ALK and McMaster's work on a type-2 memory B cell
Official profile sources: Allergy vaccines | ALK · Our company | ALK
Current 2026 update
What is changing at ALK-Abello in 2026?
By August, ALK's 2026 story had moved from approvals towards launches, reimbursement and pipeline execution. Q2 tablet sales rose 22% to DKK 1,013 million, 56% of revenue, while early neffy revenue remained modest.
The change in one sentence
The portfolio is moving from regulatory milestones to access and execution.
neffy 2 mg has reached ten markets; paediatric tablets are moving through launches and reimbursement decisions; peanut phase 3 planning meets new R&D leadership.
Four lenses on 2026
The same four-quadrant format used in the Company profile.
01 · Rescue treatment
neffy moves from approval into early launches
As of ALK's 20 August Q2 report, the ARS-developed neffy 2 mg nasal spray had launched in ten markets, most recently Canada on 5 August, for adults and children weighing at least 30 kg. Five European launches occurred around quarter-end. The lower-dose 1 mg version for children aged at least four and weighing 15–30 kg was approved in Europe, but its first launches were still expected later in 2026 and it remained under Canadian regulatory review. Q2 neffy revenue increased but stayed modest as reimbursement continued; UK work to convert national approval into regional access is expected to extend beyond 2026. ALK holds commercial rights in defined territories and a US co-promotion role; it did not develop the molecule.
- Current signal2 mg launched in 10 markets as of 20 August · 1 mg European launches pending · revenue still modest
- Why it mattersThe anaphylaxis franchise is crossing from regulatory approval into market-by-market execution, where reimbursement and adoption now matter.
- Q2 product launches and pipeline ALK · 20 August 2026
- Canada neffy 2 mg launch ALK · 5 August 2026
02 · Paediatric access
Children's tablets move through launches and NICE final-draft review
At Q2, ALK's house-dust-mite tablet was approved for paediatric use in 36 countries and launched in 22; the tree-pollen tablet was approved for children and adolescents in 20 countries and launched in 13. ALK links the roll-out to new tablet patients and growth. On 14 August, NICE issued Final Draft Guidance recommending ITULAZAX for ages 5–17 with birch-pollen allergy and ACARIZAX for ages 5–11 with house-dust-mite allergy. ALK expected Final Guidance later in August, after which relevant NHS systems would implement it. Direct NICE project pages checked through the cutoff still listed both appraisals as in development, so completed Final Guidance and immediate NHS availability are not assumed.
- Current signalHDM tablet 36 approvals, 22 launches · tree tablet 20 approvals, 13 launches · NICE final draft
- Why it mattersThe core tablet franchise is broadening to children, but country launch counts and a favourable final draft do not by themselves prove routine access or prescriptions.
- Q2 product launches and pipeline ALK · 20 August 2026
- NICE paediatric final draft ALK · 14 August 2026
- NICE ITULAZAX project status NICE · Checked 28 August 2026
- NICE ACARIZAX project status NICE · Checked 28 August 2026
03 · Pipeline and leadership
Peanut phase 3 planning meets a new Global R&D leader
In ALLIANCE, a phase 2 trial of 150 patients aged 4–65, ALK reported that 49% at the highest dose tolerated 300 mg of peanut protein after 24 maintenance weeks versus 18% on placebo, with no treatment-related anaphylaxis or serious adverse events. The result stays inside that investigational trial. Q2 says phase 3 preparation remains on track for initiation before year-end, subject to final regulatory dialogue on design. Jacob Glenting becomes EVP and head of Global R&D on 1 September, filling a role vacant since February. He moves from portfolio and product strategy after earlier commercial and licensing work involving Torii/Shionogi, Abbott, GenSci and ARS; ALK describes his remit as balancing core innovation with adjacent allergy areas and partnerships.
- Current signal49% vs 18% at the phase 2 TD300 endpoint · phase 3 regulator-dependent · new R&D head from 1 September
- Why it mattersAn investigational food-allergy programme is approaching a pivotal design decision as responsibility for the broader Allergy+ pipeline changes hands.
- Q2 product launches and pipeline ALK · 20 August 2026
- Peanut-tablet phase 2 ALK · 20 April 2026
- Global R&D appointment ALK · 20 August 2026
04 · What to watch
Three questions for the next disclosures
Three near-term events will show whether 2026's approvals convert into durable access and pipeline progress.
- NICE final guidanceDoes NICE publish Final Guidance for ITULAZAX and ACARIZAX, and how quickly do relevant NHS systems implement it?
- neffy 1 mg and reimbursementDoes the paediatric dose launch in Europe and clear Canadian review, while reimbursement lifts revenue beyond its current modest level?
- Peanut phase 3Does regulatory dialogue conclude in time for the trial to begin before year-end under the incoming Global R&D head?
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 59 | +39% | +256% | +138% |